Prosecution Insights
Last updated: May 29, 2026

Examiner: DICKENS, AMELIA NICOLE

Tech Center 1600 • Art Units: 1645 1671 1678

This examiner grants 48% of resolved cases

Performance Statistics

48.2%
Allow Rate
-11.8% vs TC avg
155
Total Applications
+22.6%
Interview Lift
1276
Avg Prosecution Days
Based on 112 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
14.5%
§102 Novelty
31.2%
§103 Obviousness
27.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17335578 METHODS FOR ASSESSING EFFICACY OF A DRUG IN VIVO BY MONITORING ADME PROTEINS IN EXTRACELLULAR VESICLES Final Rejection Purdue Research Foundation
18604196 METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES Final Rejection MarvelBiome, Inc.
18292542 VACCINE COMPOSITIONS COMPRISING BRUCELLA STRAINS AND METHODS THEREOF Non-Final OA THE TEXAS A&M UNIVERSITY SYSTEM
18457299 RECOMBINANT MICROORGANISMS AND USES THEREFOR Non-Final OA LanzaTech, Inc.
18949811 APPLICATION OF T1FR PROTEIN IN INHIBITION OF PATHOGENICITY OF ADHERENT-INVASIVE ESCHERICHIA COLI (AIEC) Non-Final OA Sichuan University
18167664 Microbially Induced Inflammation Produces Changes in Distinct Healthy Tissues in Human Oral Cavity Final Rejection Colgate-Palmolive Company
17927139 A LIVE STRAIN OF STAPHYLOCOCCUS AUREUS AND USES THEREOF Final Rejection Versitech Limited
18392130 ANTIMICROBIAL PEPTIDES AND MODIFICATIONS THEREOF Non-Final OA Donald Danforth Plant Science Center
17943587 CHIMERIC RECOMBINANT PROTEIN ENCODING EPITOPES WITH IDENTITY TO BACTERIAL, FUNGAL, PARASITE AND HUMAN METABOLIC ENZYMES INVOLVED IN PATHOGENESIS DURING SEXUALLY TRANSMITTED INFECTIONS Non-Final OA Washington State University
18675831 TREATING OR PREVENTING RESPIRATORY INFECTION Non-Final OA Telethon Kids Institute
18029640 COMPOSITIONS COMPRISING INACTIVATED MICROBES, AND METHODS FOR USE AND PRODUCTION THEREOF Final Rejection Colorado State University Research Foundation
18430704 Probiotic composition comprising Bacillus clausii UBBC-07 for modifying Gut microbiome in IBD patients Final Rejection Unique Biotech Limited
18691412 RECOMBINANT GLYCAN BINDING PROTEINS AND ITS USE Non-Final OA UNICHEM LABORATORIES LIMITED
18555540 BACILLUS SUBTILIS FNFH_BS08 AND USE THEREOF Non-Final OA ZHEJIANG OCEAN UNIVERSITY
18328308 ANTAGONIST MICROORGANISMS FOR INHIBITING FIRE BLIGHT AND COMPOSITION FOR INHIBITING FIRE BLIGHT WITH THE SAME AS ACTIVE INGREDIENT Final Rejection KNU-INDUSTRY COOPERATION FOUNDATION
18245446 PARABACTEROIDES DISTASONIS STRAINS FOR USE THEREOF IN THE TREATMENT AND PREVENTION OF GASTROINTESTINAL DISEASES AND OF DISORDERS ASSOCIATED WITH GASTROINTESTINAL DISEASES Non-Final OA INSTITUT NATIONAL DES SCIENCES ET INDUSTRIES DU VIVANT ET DE L'ENVIRONNEMENT
18159550 Lyophilized Live Bordetella Vaccines Non-Final OA ILiAD Biotechnologies, LLC
17768138 Natural non-pathogenic microorganisms capable of associating glycolipids or lipopeptides and use thereof Non-Final OA ACARYON GMBH
17435615 ANTIBODY MOLECULES AND USES THEREOF Non-Final OA THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
16329538 METHODS OF IDENTIFYING EPITOPES Final Rejection OBLIQUE THERAPEUTICS AB

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month